Top Markets
Coin of the day
Vincerx Pharma, Inc. Vincerx Pharma, Inc.

Vincerx Pharma, Inc.

VINC
Pozycja w akcjach #40889
Vincerx Pharma, Inc. is a biopharmaceutical firm currently in the clinical... Vincerx Pharma, Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to discovering and advancing innovative treatments for cancer, specifically addressing areas of high medical need within the U.S. Its primary therapeutic asset is VIP152, an inhibitor targeting cyclin-dependent kinase-9 (CDK9), designed for individuals battling advanced forms of cancer. Beyond this lead candidate, the company's pipeline features several preclinical-stage projects: VIP217, an orally administered PTEFb/CDK9 inhibitor; VIP236, a small molecule drug conjugate aimed at solid tumor treatment; and VIP943 and VIP924, both geared towards treating blood cancers. Established in 2019, Vincerx Pharma is based in Palo Alto, California.
Cena akcji
$0.0127
Ostatnia synchronizacja: 2026-08-12
Kapitalizacja rynkowa
$66.48K
Zmiana (1 dzień)
-2.31%
Zmiana (1 rok)
-67.44%
Kraj
US
Handel Vincerx Pharma, Inc. (VINC)

Kategoria

Historia stopy dywidendy dla Vincerx Pharma, Inc. (VINC)
Stopa dywidendy (TTM) dla Vincerx Pharma, Inc. (symbol akcji: VINC) na dzień 2026 wynosi: 0
Średnia stopa dywidendy z ostatnich 5 lat: 0.00%
Historia stopy dywidendy dla Vincerx Pharma, Inc. (VINC) od 2026 do 2026
Stopa dywidendy na koniec każdego roku (TTM)
Rok Stopa dywidendy Zmień
Za mało danych dla podanych dat.
Stopy dywidendy (TTM) dla podobnych firm lub konkurencji